media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Vir Biotechnology Enters Multi-Program Collaboration with Gilead Sciences to Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

On October 14, 2026, Vir Biotechnology, Inc. (Nasdaq: VIR) announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. The collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise. This is the Company’s second collaboration building on the universal PRO-XTEN® masking technology. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its proprietary dAIsY™ (data AI structure and antibodY) platform for rapid, multiparameter optimization of high-quality TCEs and the universal PRO-XTEN® masking technology to develop next-generation TCEs, each with potent anti-tumor activity and a wide therapeutic index across solid tumor targets addressing areas of high unmet need. “We believe TCEs have ...
- Source: drugdu
- 38
- October 16, 2026
Subsidiary’s YKYY036 Injection Receives Clinical Trial Approval from NMPA and FDA

People’s Finance News, October 13th – Yuekang PharmaceuticalOn October 13, (688658) announced that its subsidiaries, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. of Yuekang Pharmaceutical Group, recently received approval notices from the National Medical Products Administration (NMPA) for the use of YKYY036 injection for obese or overweight patients. Simultaneously, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. recently received a letter from the U.S. Food and Drug Administration (FDA) approving its application for clinical trials of YKYY036 injection for overweight or obese patients. Source: https://finance.eastmoney.com/a/202610133894283434.html
- Source: drugdu
- 41
- October 16, 2026
BioNTech’s mRNA Cancer Vaccine BNT113 Falls Short of Primary Endpoint in Phase 3 Trial

On October 13, BioNTech announced the first top-line results of its AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for its mRNA cancer immunotherapy candidate BNT113 . Unfortunately, BNT113 in combination with pembrolizumab as first-line treatment for unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head and neck squamous cell carcinoma failed to meet the first of the dual primary endpoints—progression-free survival —and did not statistically demonstrate a significant improvement over pembrolizumab monotherapy. Following the announcement, BioNTech’s stock price fell by about 6% during trading, casting a shadow over market enthusiasm for the mRNA tumor vaccine sector once again. It is important to note that this setback does not equate to a complete failure of the trial. The independent data monitoring committee recommends that the trial proceed as planned and that the second dual primary endpoint—overall survival—be assessed. According to the pre-specified statistical design of the trial, even if the progression-free survival (PFS) endpoint ...
- Source: drugdu
- 41
- October 16, 2026
Foghorn Therapeutics’ Collaboration Terminated by Eli Lilly; Company to Lay Off 40% of Its Workforce

recently announced that Eli Lilly has terminated its collaboration with the company . The core SMARCA2 selective inhibitor FHD-909 failed to demonstrate the efficacy required to advance to the expansion phase in Phase I dose escalation, and the related SMARCA2 degrader project has also been discontinued. Following the announcement, Foghorn’s stock price plummeted, falling by more than 40% at one point during the day , leaving its market capitalization at only about $130 million. As a result, Foghorn’s board of directors approved a restructuring plan that would reduce its workforce by about 40% , bringing the total number of employees down to about 65, in order to extend its cash runway to the second half of 2029. Why did a four-year collaboration end so suddenly? Why was the cooperation terminated? The key to understanding Eli Lilly’s “return” lies in understanding the decision-making logic of MNCs in the early stages of ...
- Source: drugdu
- 44
- October 16, 2026
Visara (USA) Acquires Overseas Rights to Haite Bio’s HT006.2.2 Eye Drops

On October 13, 2026, Haitai Bio (300683.SZ) announced that it had signed an exclusive cooperation and licensing agreement with Visara, Inc., a US company, regarding the HT006.2.2 eye drop project. According to the agreement, Visara will obtain exclusive rights outside of Greater China to develop, commercialize, manufacture, contract manufacture, use, sell, offer for sale, import, export, and otherwise utilize the licensor and licensed products of HT006.2.2 eye drops. HT006.2.2 eye drops are a recombinant human nerve growth factor (rhNGF) ophthalmic formulation independently developed by the company with independent intellectual property rights, targeting tropomyosin receptor kinase A (TrkA) and p75 neurotrophic factor receptor (p75NTR). Visara will pay the company an upfront payment of US$7 million plus recent milestone payments. Depending on the progress of clinical development and commercialization, Haitai Bio will also be entitled to receive milestone payments related to research, registration, and commercialization up to a maximum of US$104 million. ...
- Source: drugdu
- 42
- October 16, 2026
Asia Pacific Pharmaceutical’s Shengyao Guangyan Obtains a New Acne Drug Technology Achievement from Quzhou Fudan Research Institute

On October 13, 2026, Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (hereinafter referred to as “Shengyao Guangyan”), a wholly-owned subsidiary of Asia Pacific Pharmaceutical (002370.SZ), signed a “Letter of Intent for Cooperation on Innovative Drug Technology Transaction” with Quzhou Fuda Biomedical Innovation Research Institute (hereinafter referred to as “Quzhou Fudan Research Institute”), intending to introduce all the technological achievements of the Class 1.1 small molecule innovative drug “a BODIPY photosensitizer for acne treatment” held by Quzhou Fudan Research Institute . The target project of this collaboration is a Class 1.1 small molecule innovative drug, “A BODIPY-type photosensitizer for acne treatment,” belonging to the cutting-edge field of photodynamic therapy. It is currently in the PCC (preclinical candidate compound) stage, with one Chinese patent application filed. The indication is acne and other applications. The transaction consideration includes a total of RMB 25 million for R&D and approval milestone payments, a total commercialization milestone ...
- Source: drugdu
- 34
- October 16, 2026
Zelgen Submits a Marketing Application in China for Gecacitinib in Ankylosing Spondylitis

On October 14, 2026, Zekjing Biotechnology (688266.SH) announced that it had submitted a third marketing application for gecacitinib to the National Medical Products Administration for the treatment of active ankylosing spondylitis. Gecacitinib is a novel JAK inhibitor independently developed by the company, which owns the intellectual property rights to the product. Previously, the drug had been approved for marketing by the National Medical Products Administration for two indications: the treatment of intermediate- to high-risk myelofibrosis and severe alopecia areata in adults. The myelofibrosis indication has been included in the 2025 National Reimbursement Drug List. Ankylosing spondylitis is an arthritis characterized by long-term inflammation of the spinal joints, typically manifesting as inflammation of the sacroiliac joints and spinal entheses. The Chinese market for ankylosing spondylitis drugs is projected to reach RMB 17 billion by 2025, with a compound annual growth rate of 12.1% from 2020 to 2025. Source: https://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650033491&idx=2&sn=0acfe69713aae899421bc4c8d33101c2&chksm=89939f3bf89bb9f002129378fbe4bfc53f860
- Source: drugdu
- 30
- October 16, 2026
Teva Announces U.S. FDA Approval of WELTRUZA™ (olanzapine) Extended-Release Suspension for Injection

WELTRUZA™ (olanzapine) extended-release suspension for injection is the first and currently the only approved long-acting olanzapine injection (LAI) for the treatment of schizophrenia in adults, administered subcutaneously once a month; treatment requires no loading dose, no oral medication supplementation, and no post-injection monitoring. This approval is based on the results of the pivotal Phase III SOLARIS study. The study showed that WELTRUZA improved overall symptoms, significantly reduced disease severity, and improved individual and social functioning; its systemic safety profile was consistent with that of oral olanzapine.¹ As Teva continues to advance its global “Pivot to Growth” strategy, it will further fulfill its commitment to innovation in the field of patient-centered neuroscience and continue to build a differentiated portfolio of long-acting injectable products. On October 9, Teva Pharmaceutical Industries (NYSE and Tel Aviv Stock Exchange: TEVA) announced that WELTRUZA™ (olanzapine) extended-release suspension for injection has been approved by the U.S. Food ...
- Source: drugdu
- 35
- October 16, 2026
【EXPERT Q&A】If there are no inquiries for a silver member product one month after its launch, what issues should be checked first?

Drugdu.com expert’s response: Suppliers tend to get extremely anxious when their Silver Member products have been online for a month without receiving any inquiries. This reaction is completely understandable. Enterprises sign up for membership, upload products, and wait for overseas buyers to reach out. After a month with no inquiries, it is easy for them to assume the platform is ineffective or their products have no market demand. However, from the perspective of platform operation, the lack of inquiries in the first month should not be judged solely by the result, nor can it be simply concluded that “there are no buyers”. Especially for B2B products such as pharmaceuticals, medical devices, APIs, excipients and consumables, there is an inherent screening process before buyers officially send an inquiry: from searching, browsing, comparing suppliers to making the final decision. Whether the products can be seen, matched by search algorithms, understood and trusted ...
- Source: drugdu
- 42
- October 16, 2026
Oman Health

Organiser：Oman Exhibition Group Time：September 21-23, 2026 Address：P.O. Box 117, P.C. 111, Muscat International Airport, Oman Exhibition hall：Oman International Exhibition Center Product range: Hospital equipment, devices and technologies Surgical instruments, medical-related books, X-ray, CT, MRI, nuclear medical imaging, pharmaceutical and herbal products, home medical equipment, physical therapy, pharmaceutical raw materials, anesthesiology, respiratory equipment, pharmaceutical and packaging equipment, surgical technologies and devices, health care pharmaceuticals, sterilization and disinfection equipment, chemical clinical automatic instruments, first-aid medical equipment and supplies, biotechnology laboratory equipment, surgical instruments and endoscopic equipment, blood bank equipment and refrigeration equipment, general and special diagnostics, dental care and treatment equipment, orthopedic technology and rehabilitation devices, oral care About Oman Health： Oman Health is the largest and most influential medical exhibition in Oman. It showcases products including laboratory equipment, instruments, laboratory supplies, emergency management solutions, medical information and communication technologies, security systems, medical facility design and construction technologies, quality control ...
- Source: drugdu
- 51
- October 15, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.